A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast CancerBogang Wu, Leif W. Ellisen, Steven J. Isakoff et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 5
Current and Emerging Role of Antibody–Drug Conjugates in HER2-Negative Breast CancerRachel O. Abelman, Aditya Bardia, Laura M. Spring et al.|Hematology/Oncology Clinics of North America|2022Cited by 4